The company recently announced that DR Alberto Sola, CO-Founder of Universal Ibogaine, will present his recent findings in the title Ibogaine Hydrochloride and Acute Opioid Detox.
The trading just got a green signal on the TSX-V, and $IBO zoomed past the fellow penny stocks in a flicker; what a scene it was; I am amazed and satisfied to buy some shares of it
Let’s go fellow shareholders of $IBO it is the day to be proud of yourself for trusting in $IBO, I am so enlivened to see this stock reaching the heights it was always meant to reach
UI CEO made a statement "Our capital markets and investor relations strategy includes the FSE listing. We recently began trading on the OTCQB Exchange in the United States, and curiosity in the UI story is growing in Europe, particularly Germany. With a mushrooming market and interest in psychedelic medications, Germany has a reputation for innovation and leadership."
$IBO is moving ahead with courage and compassion on the TSX-V, the stock is expanding in leaps and bounds in the market, shares are effectively trading at $0.0400 with zero loss percentage
$DIA has marked a rather brilliant opening on the TSX-V and is moving ahead with an unmatched pace and stock trading at suitable buying price of $0.1800 to generate heavy profit
$IBO don’t ever shy out from attaining peaks in the market and delivering unimaginable profit to the shareholders, the shares are trading yesterday with a massive spike of 10% at $0.0500 with sizeable ascent
UI's common shares have been listed for trading on the Frankfurt Stock Exchange, or Bourse Frankfurt, under the ticker symbol "JC4". In Canada, UI will continue to trade on the TSX Venture Exchange under the ticker IBO and on the OTCQB under the ticker symbol IBOGF.
$IBO is one of the handpicked penny stocks in the market today and is racing ahead with full speed, the stock’s financial figures are pretty neat and is expected achieve great heights in the days to come, shares are trading yesterday at $0.0500 with a distinctive spike
The Frankfurt Stock Exchange (FSE) is Germany's largest stock exchange and the leading European destination for Canadian venture capital firms seeking exposure and liquidity in the European market. The FSE enables advanced electronic trading, settlement, and information technologies, allowing it to handle the increasing demands of cross-border trading.
"H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
$IBO one of the TSX-V’S finest stocks is trading with an uphill incline and is catering twofold revenue to the investors already the shares are trading
At the Kelburn Clinic, UI is developing a cutting-edge holistic addiction treatment protocol that, when combined with the anticipated ibogaine detox programme, will transform the way we treat addiction and dramatically enhance the lives of individuals and families plagued by addiction.
$IBO has been resilient through the ebbs and flows of the market and have always maintained a tight toe hold in the Canadian venture exchange, its consistency to this day is what intrigues investors globally, the last closing price was $0.045.
Under the ticker symbol "JC4", UI's common shares have been registered for trade on the Frankfurt Stock Exchange, or Bourse Frankfurt. In Canada, UI will continue trading under the ticker name IBO on the TSX Venture Exchange and on the OTCQB under the ticker symbol IBOGF on the OTCQB
UI is developing an advanced holistic addiction treatment protocol, at its Kelburn Recovery Centre, that when combined with the planned ibogaine detox methodology is expected to transform the way we treat addiction and dramatically promote the welfare of families affected by addiction.
UI CEO made a statement "Our capital markets and investor relations strategy includes the FSE listing. We recently began trading on the OTCQB Exchange in the United States, and curiosity in the UI story is growing in Europe, particularly Germany. With a mushrooming market and interest in psychedelic medications, Germany has a reputation for innovation and leadership."
The H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond will feature a presentation from UI CEO Nick Karos. On June 27, 2022, a hybrid online and offline event will take place.
